Tag: NASDAQ: CBAY

  • Top 5 Penny Stocks Under 5 Dollars To Buy Right Now

    Stocks that trade under the 5 Dollar mark, which are better known as penny stocks remain a favorite to a significant portion of the financial market. They are especially popular amongst retail traders that seek immediate short-term swings. Furthermore, in many cases, long-term investors identify highly promising penny stocks which they anticipate will eventually soar after several years. The attraction with this class of stock primarily lies in the growth potential they theoretically hold. Hardly any other stock category rises by such an enormous growth factor as one which is at the bottom of its trajectory.

    Additionally, people tend to like holding a large number of assets, as opposed to fewer of them. This psychological motivation is one out of many factors as to why large companies go for stock splits. Given this preference that many hold for penny stocks, we recommend the top 5 stocks trading under $5, which you can add to your portfolio.

    Penny stocks image

    CymaBay Therapeutics

    We begin our list of Stocks Under 5 Dollars with the highly promising biopharmaceutical company, CymaBay Therapeutics (NASDAQ: CBAY). This penny stock is a great long-term investment to consider, especially given the progress the company has made in recent times. Its treatment candidate targeting primary biliary Cholangitis, otherwise known as PBC, has covered some significant milestones, with phase 3 results anticipated by next year. The prior studies each indicated a decrease in patients’ PBC scores, whilst enhancing the survival rate of patients that do not have a transplant carried out.

    For a stock trading at a mere $4.16, these results are incredible in terms of the potential they hint at. The PBC market is presently estimated at being worth $800 million and is likely to reach $2.5 billion, according to trends and statistics. With CymaBay’s candidate anticipated to be the leading treatment mode for the condition, approval for commercialization could be a game changer for the company.

    On the financial front, CBAY stands in a relatively decent position, considering it is in a pre-revenue phase in its lifecycle. The company’s cash and equivalents stand at $193 million, which is a clear indication that each of its studies can be funded without obstacles. Given these aspects, CBAY is an ideal penny stock to consider investing in. As more positive news comes about pertaining to its treatment candidates, we can expect its price to further surge.

    ARC Document Solutions

    The second stock Under 5 Dollars on this list is the digital printing company, ARC Document Solutions (NYSE: ARC). ARC trades at $2.95 and is a stock that holds significant promise, especially for investors that don’t mind facing a certain degree of risk. Trends in the last years have shown decreasing business performance for the company, yet it seems to be making an epic turnaround following the end of the Covid-19 pandemic. Demand for ARC’s specialist printing services has been growing.

    ARC Document Solutions is a master of its craft and prints high-quality materials in a number of different mediums. With 10,800 sites in operation across the United States, the company holds a stellar market position. Moreover, the company has taken a unique approach to offer the full set of advantages to its printing clients, which gives it a significant competitive edge. For one, it offers printer networking services, which allows organizations to remotely connect to the various printers on the network, as well as its own ARC printing centers. It also offers software packages for clients that would allow them to track and subsequently optimize their print usage and expenses.

    The company’s success given its robust market position further reflects in its financial results over the years. 2017 was the worst year for the company, where it incurred a net loss of over $21 million. By 2020, despite Covid-related challenges, it delivered a net profit of an impressive $6.2 million, in comparison to the prior year’s $3 million figure. Its recent most annual earning figure for 2021 stands at an incredible $9.1 million.

    Both these financial trends, as well as its strong market position, make its rise inevitable in the long-term, and a must-buy for those interested in growing penny stocks.

    Assertio Holdings Inc

    Up next, we present the specialty pharmaceutical company, Assertio Holdings Inc (NASDAQ: ASRT). There is much to marvel at about this emerging player, but the most impressive is how far it has progressed and transformed itself in recent years. To put this into context, the last 12 months have seen the S&P500 fall by almost 11%. At the same time, ASRT climbed from $1.20 to $4, indicating a gain of almost 233%.

    The credit for this stellar growth trajectory goes to its fresh management that turned things around for the company. Last year, under the older management structure, cash flow for the company looked dismal, and a poor acquisition of the opioid drug Nucynta was made. Things for Assertio looked bleak. However, with a new management team on board, a number of critical changes were made, significantly boosting the company’s standing and making it one of the finest investments for Stocks Under 5 Dollars. For one, the terrible Nucynta deal was reversed, with the asset being disposed off without delay, and its proceeds used to pay off company debts. This was crucial in enhancing Assertio’s net asset worth and reducing credit risk.

    In addition to debt settlement, the management had gone on to acquire a portfolio of non-steroidal anti-inflammatory drugs. This move proved highly beneficial to the company, as it provided a much-needed boost to its cash flow. Analysts have projected its revenue to climb from $112 million to a whopping $136 million. Similarly, its EBITDA figure is anticipated to climb from $49 million to nearly $72 million.

    With prospects this strong, any stock is sure to continue its epic rise. The penny stock is simply too good to ignore.

    US Global Investors

    The fourth stock  Under 5 Dollars on our list is the small-cap, publicly owned, investment management firm, US Global Investors (NASDAQ: GROW). US Global provides services to both pooled investment vehicles, as well as other investment companies. This is due to the financial expertise its management holds in managing various classes of investment funds.

    There are a number of attraction factors that are inherent to GROW. For one, the company presently holds a market capitalization of $60 million, with its shares priced at nearly $4.20 each. An acquisition offer by Echo Lake Capital and Deer Haven have placed an offer value of $5.30 per share, which implies a company valuation of over $80 million. This indicates a considerable undervaluation, with a rise imminent. However, this offer does not adequately reflect how high GROW’s intrinsic value actually is.

    According to valuation calculations made by the company’s management, GROW’s ETF business alone has a potential valuation of over $100 million. Moreover, its PE ratio is significantly below that of its competitors, further reinforcing undervaluation. This is likely due to the mass sell-off the company’s stock was caught up in, during the prior year, which saw its price shed by nearly 30%. However, its fundamentals remain strong despite the wider panic of the bear market.

    Furthermore, GROW is a debt-free company, which enhances its safety profile, and makes it worth consideration, especially when factoring in the macroeconomic headwinds and recessionary conditions. All of these aspects point to the strength this penny stock holds, and why it is worth including in any investor’s portfolio.

    Safe Bulkers Inc

    The final stock Under 5 Dollars on our list is the dry-bulk transportation services provider, Safe Bulkers Inc (NYSE: SB). This penny stock is a top pick among investors in terms of the incredible discount its price currently trades at. This is evident from its PE ratio of 2.7, which is substantially lower than the industrial average of 16.2.

    In addition to its attractive valuation, SB has always been a favorite amongst shipping investors. This is due to the stability it offers, as well as its prudent financial management. Its 50 dry-bulk vessels offer it exposure to some of the most lucrative shipping markets such as Panamax, Kamsarmax as well as Post-Panamax. For the first quarter of 2022, the company saw its revenue climb to almost $78 million, compared to the prior year’s first quarter figure of $62.5 million. Similarly, its net income rose from $21 million to over $36 million during the same time period.

    At present, the management remains focused on ensuring dividend growth, as well as deleveraging its balance sheet, both of which are likely to catalyze further growth in its share price. Revenue is also likely to increase with time, given that lower-rate legacy charter contracts continue to expire.

    Things are looking good for Safe Bulkers, especially in terms of its growth prospects and financial improvement. The features discussed to make it the ideal penny stock to lock an early position in, and ride its steady growth wave over time.

    Conclusion

    Penny stocks Stocks Under 5 Dollars are a sure way for any investor to see their portfolio get an early boost, given the high growth potential this class of stock offers. With strategic planning and the right choices, you can significantly boost your chances of success for such an investment strategy, by identifying the most promising stocks to buy. Each of the stocks covered in this article showcase stellar opportunities from a wide array of industries and areas. These stocks also hold unique strengths which make growth inevitable and imminent.

  • Here’s Top 25 Biotech Stocks For September 2020

    Here’s Top 25 Biotech Stocks For September 2020

    One thing constant in the world is change. As time passes there are many industries that are undergoing changes as they expand their businesses and bring new innovations. One of the industries that are known for their constant change is the biotechnology industry.

    The biotech industry is continuously changing in every aspect of daily existence with new technological breakthroughs and advancements in knowledge. Companies are constantly striving to bring new medicines and vaccines to deal with the diagnosis.

    Let’s have a look at the top 25 biotech companies which are continuously adding new trends in the market:

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares were trading up 171.59% at $34.22 at the time of writing on Monday.

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) share price went from a low point around $10.09 to briefly over $37.00 in the past 52 weeks, though shares have since pulled back to $34.22. AIMT market cap has remained high, hitting $2.13B at the time of writing, giving it a price-to-sales ratio of more than 3550.

    If we look at the recent analyst rating AIMT, Cowen initiated coverage on AIMT shares with an Outperform rating. Aimmune Therapeutics recently disclosed it has signed an agreement with Nestle S.A. As per the agreement, Nestle will pay $34.50 per share in an all-cash transaction.

    Akcea Therapeutics Inc. (AKCA) last closed at $18.28, in a 52-week range of $8.00 to $22.79. It has been disclosed yesterday that Ionis Pharmaceutical has bought the 24% shares of Akcea it hasn’t owned earlier for $18.15 per share in cash. This acquisition is one step forward to make a strong and efficient organization that gives benefits to all shareholders.

    Capricor Therapeutics Inc. (NASDAQ: CAPR) Shares headed rising, higher as much as 14.64% after Capricor Therapeutics to Present at The LD 500 Virtual Conference. Capricor market capitalization is 115.11 million. The most recent rating by Maxim Group, on December 26, 2018, is at a Hold.

    Capricor Therapeutics, a clinical-stage biotechnology company has disclosed earlier that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a Phase 2 clinical trial of CAP-1002 in COVID-19 patients.

    Apellis Pharmaceuticals Inc. (APLS) stock soar by 14.74% to $30.83. The most recent rating by ROTH Capital, on July 20, 2020, is at a Buy. Its stock fluctuated between the 52-weeks low range of $16.85 and a 52-weeks high range of $45.04. It has moved up 82.97% from its 52-weeks low and moved down -31.55% from its 52-weeks high.

    Xeris Pharmaceuticals Inc. (NASDAQ: XERS) rose 10.71% after gaining more than $0.45 on Monday. Xeris, a specialty pharmaceutical company disclosed August 26, 2020, that the Compensation Committee of Xeris’ Board of Directors awarded non-qualified stock options for an aggregate of 500 share of its common stock to 1 new employee under the Inducement Equity Plan of Xeris.

    Xeris share price went from a low point around $1.42 to briefly over $12.29 in the past 52 weeks, though shares have since pulled back to $4.71. It has traded up $231.34% from its 52-weeks low and has traded down -61.72% from its 52-weeks high.

    9 Meters Biopharma Inc. (NASDAQ: NMTR) shares headed rising, higher as much as 7.73%. It has disclosed Monday that it has decided to form the scientific advisory board (SAB). The SAB includes an acclaimed group of six experts in the gastroenterology field with sub-specialties in celiac disease, inflammatory bowel disease (IBD), and functional GI diseases. 9 Meters have gained +0.05 during its trading on Monday. It has moved up 76.17% and moved down -49.46% from its 52-weeks low and high range, respectively.

    VBI Vaccines Inc. (NASDAQ: VBIV) rose 6.77% after gaining more than $0.27 on Monday. VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020. During the presentation, Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study, Adam Finn, M.D., Ph.D., revealed the encouraging points of hepatitis B antibodies. VBI Vaccines traded up 815.15% from its 52-weeks low and traded down -38.53% from its 52-weeks high.

    CymaBay Therapeutics Inc. (NASDAQ: CBAY) rose 5.37% after gaining more than $0.33 on Monday. It has disclosed the result of Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). The data presented at electronic presentation showed the safety and efficacy of seladelpar over 1 year of open level treatment. These findings suggest that seladelpar treatment in a high-risk PBC patient population promotes clinically significant improvement.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) rose 4.53% after gaining more than $0.18 on Monday. BioCryst Inc disclosed Monday it has received Orphan Drug Desigantion from FDA for its oral Factor D inhibitor, BCX9930. It is used for the treatment paroxysmal nocturnal hemoglobinuria (PNH). It has moved up as its announced it has received the $44 million  National Institute of Allergy and Infectious Diseases (NIAID). This amount is awarded to BCRX by NIAID to support the development of galidesivir.

    ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Shares headed rising, higher as much as 4.24%. The most recent rating by Raymond James, on August 25, 2020, is at an Outperform. ACADIA Inc has announced earlier that it has bought CerSci Therapeutics.

    Immunomedics Inc. (IMMU) stock soar by 6.37% to $44.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics stock has fluctuated between the 52-weeks low and high range of $8.80-$44.91, respectively.

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) last closed at $114.22, in a 52-week range of $72.67 to $121.50. Analysts have a consensus price target of $141.47.

    Seres Therapeutics Inc. (NASDAQ: MCRB) stock soar by 8.21% to $26.49.  It has moved upward 951.19% from its 52-weeks low and moved down -19.73% from its 52-weeks high. The most recent rating by Piper Sandler, on August 18, 2020, is at an Overweight.

    Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) last closed at $29.51 after gaining +2.54 on Monday. It has a 52-week range of $12.99 to $27.97. It has moved up 127.17% and 5.51% from its 52-weeks low and high, respectively. Analysts have a consensus price target of $32.88.

    Geron Corporation (NASDAQ: GERN) Shares headed rising, higher as much as 6.22%. The most recent rating by Stifel, on August 03, 2020, is at a Buy.

    Sesen Bio Inc. (NASDAQ: SESN) rose 6.19% after gaining more than $0.06 on Monday. SESN’s stock has changed between the 52-weeks low range of $0.37 and a high range of $1.52. It has moved up and moved down 178.38%, -33.12% from its 52-weeks low and high, respectively.

    Kadmon Holdings Inc. (NYSE: KDMN) last closed at $5.00, in a 52-week range of $2.04 to $5.50. It has traded up 145.10% from its 52-weeks low and traded down -9.09% from its 52-weeks high. Looking at its liquidity, its current ratio is 6.20.

    Evofem Biosciences Inc. (EVFM) stock soar by 6.07% to $3.32 after Evofem Biosciences to Participate in Four Upcoming Investor Conferences. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    MacroGenics Inc. (NASDAQ: MGNX) Shares headed rising, higher as much as 6.01%. The most recent rating by Citigroup, on August 03, 2020, is at a Neutral.

    Iovance Biotherapeutics Inc. (NASDAQ: IOVA) last closed at $33.33, in a 52-week range of $17.67 to $41.49. Analysts have a consensus price target of $47.08.

    Surface Oncology Inc. (NASDAQ: SURF) stock soar by 5.01% to $6.50. The most recent rating by Wedbush, on August 28, 2020, is at an Outperform.

    Fortress Biotech Inc. (NASDAQ: FBIO) Shares headed rising, higher as much as 4.63% after LD Micro — 360 Companies Set to Present this Week. The most recent rating by B. Riley FBR, on December 18, 2019, is at a Buy.

    Synthetic Biologics Inc. (SYN) last closed at $0.64, in a 52-week range of $0.25 to $0.75. It has moved up 153.17% from its 52-weeks low and moved down -14.87% from its 52-weeks high.

    Zogenix Inc. (NASDAQ: ZGNX) stock soar by 4.37% to $23.67. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. ZGNX has traded up and down 42.16% and -58.63% from its 52-weeks low and high range.

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 4.18% after gaining more than $0.24 on Monday. Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference.